Panipenem
Chemical compound
- J01DH55 (WHO) (with betamipron)
- (5R,6S)-3-{[(3S)-1-ethanimidoylpyrrolidin-3-yl]sulfanyl}- 6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid
- 87726-17-8 Y
- 72015
- 16736434 N
- W9769W09JF
- D01048
- ChEMBL339323 N
- DTXSID20868982
- Interactive image
- C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)S[C@H]3CCN(C3)C(=N)C)O
InChI
- InChI=1S/C15H21N3O4S/c1-7(19)12-10-5-11(13(15(21)22)18(10)14(12)20)23-9-3-4-17(6-9)8(2)16/h7,9-10,12,16,19H,3-6H2,1-2H3,(H,21,22)/t7-,9+,10-,12-/m1/s1 N
- Key:TYMABNNERDVXID-DLYFRVTGSA-N N
Panipenem (INN) is a carbapenem antibiotic used in combination with betamipron.[1] It is not used in the United States.[citation needed]
See also
- Panipenem/betamipron
References
- ^ Goa KL, Noble S (2003). "Panipenem/betamipron". Drugs. 63 (9): 913–25, discussion 926. doi:10.2165/00003495-200363090-00005. PMID 12678575. S2CID 263994230.
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Lipopeptides |
|
---|---|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e